CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature · 2005 · 3.5K citations

Life Sciences, Genetics, Molecular Biology +7

A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders

Róbert Královics, Francesco Passamonti, Andreas Buser et al. · New England Journal of Medicine · 2005 · 3.5K citations · Full text

Life Sciences, Genetics, Hematology +15

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations

Life Sciences, Genetics, Hematology +14

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Ross L. Levine, Martha Wadleigh, Jan Cools et al. · Cancer Cell · 2005 · 3K citations · Full text

Medicine, Genetics, Hematology +14

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12